scholarly journals Validation of a modified clinical risk score to predict cancer‐specific survival for stage II colon cancer

2014 ◽  
Vol 4 (1) ◽  
pp. 84-89 ◽  
Author(s):  
Raymond Oliphant ◽  
Paul G. Horgan ◽  
David S. Morrison ◽  
Donald C. McMillan ◽  
Keyword(s):  
Colon Cancer ◽  
Risk Score ◽  
Stage Ii ◽  
Clinical Risk Score ◽  
Cancer Specific Survival ◽  
Clinical Risk ◽  
Stage Ii Colon Cancer

scholarly journals An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer

2020 ◽  
Vol 59 (12) ◽  
pp. 1503-1507
Author(s):  
Eetu Heervä ◽  
Vesa Väliaho ◽  
Tapio Salminen ◽  
Lasse Nieminen ◽  
Anu Carpelan ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Risk Score ◽  
Stage Ii ◽  
Cancer Specific Survival ◽  
Stage Ii Colon Cancer

Predictive risk-score model for selection of patients with high-risk stage II colon cancer for adjuvant systemic therapy

Surgery ◽  
2021 ◽  
Author(s):  
Richard J. Straker ◽  
Danny H.J. Heo ◽  
Adrienne B. Shannon ◽  
Douglas L. Fraker ◽  
Skandan Shanmugan ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Risk Score ◽  
Systemic Therapy ◽  
Stage Ii ◽  
Score Model ◽  
Stage Ii Colon Cancer ◽  
Predictive Risk ◽  
Selection Of Patients ◽  
Selection Of

Prognostic biomarkers in a series of stage II colon cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3629-3629
Author(s):  
Cristina Santos ◽  
Marta Terricabras ◽  
Adriana Lopez-Doriga ◽  
Sara Gonzalez ◽  
Anna Fernandez ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Braf Mutation ◽  
Cox Regression ◽  
Tumor Stroma ◽  
Stage Ii ◽  
Braf V600e ◽  
P Value ◽  
Mononucleotide Repeat ◽  
Cancer Specific Survival ◽  
Stage Ii Colon Cancer

3629 Background: Different clinico-pathological factors are used to define a group of patients with high-risk stage II colon cancer (CC) that may benefit of adjuvant treatment. Moreover, several molecular markers, such as microsatellite instability (MSI) and BRAF, have been widely investigated as prognostic factors. Recently a high stroma component (EMT+ subtypes) has also been associated with poor outcome. The aim of the study is to analyze the prognostic value of MSI, BRAF and tumor-stroma ratio in a prospective series of stage II CC patients. Methods: FFPE tissue from 432 stage II CC patients operated at Hospital Universitari de Bellvitge (1996 - 2006) were included in the study. MSI status was assessed by the analysis of 5 mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27). BRAF V600E mutation was analyzed by single strand conformation polymorphism technique. Tumor-stroma ratio was analyzed by immunohistochemistry. Associations between molecular factors and clinical features were assessed by Chi-Squared (X2) tests. A Cox regression model was used to evaluate the Relapse Free (RFS) and the Colon Cancer specific Survival. Results: MSI status could be determined in 350 patients. 48 (14%) had MSI high (MSI-H) tumor. BRAF status could be assessed in 380 cases. 58 (15%) cases were BRAF mutated. Tumor-stroma ratio was analyzed in 407 tumor samples. 176 (43%) tumors had more than 50% intra-tumor stroma and were classified as stroma-high. MSI-H tumors were significantly located in right colon (X2 p-value = 1.03e-5), were poorly differentiated (X2 p-value = 0.003) and had more than 12 lymph nodes resected (X2 p-value = 0.037). MSI-H tumors were associated with BRAF mutation (X2 p-value = 0.02) and stroma-low (X2 p-value = 0.0005). When a molecular prognostic risk classification was performed, patients with MSI-H /stroma-low suggested a low risk of relapse comparing to MSI-H/stroma-high, microsatellite stable (MSS)/stroma-low and MSS/stroma-high patients (HR = 3.15; 95 CI, 0.76 – 13.1, p-value = 0.0602). Conclusions: MSI-H tumors have BRAF mutation as well as low intra-tumor stroma. Our results suggest that tumor-stroma ratio can explain differential prognosis in MSI-H stage II tumors.

Mo1102 Clinical Risk Score and Fecal Immunochemical Testing Are Helpful to Prioritize the Patients for Colon Cancer Screening by Colonoscopy

2013 ◽  
Vol 144 (5) ◽  
pp. S-578
Author(s):  
Satimai Aniwan ◽  
Rungsun Rerknimitr ◽  
Phonthep Angsuwatcharakon ◽  
Rapat Pittayanon ◽  
Tanassanee Soontornmanokul ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Screening ◽  
Risk Score ◽  
Colon Cancer Screening ◽  
Clinical Risk Score ◽  
Fecal Immunochemical Testing ◽  
Clinical Risk

CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer

2019 ◽  
Vol 90 ◽  
pp. 70-79
Author(s):  
Matthew J. Cecchini ◽  
Joanna C. Walsh ◽  
Jeremy Parfitt ◽  
Subrata Chakrabarti ◽  
Rohann J. Correa ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Markers ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

scholarly journals Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhihao Lv ◽  
Yuqi Liang ◽  
Huaxi Liu ◽  
Delong Mo
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Prediction Models ◽  
Radical Surgery ◽  
Survival Rates ◽  
Stage Ii ◽  
Survival Prediction ◽  
Stage Ii Colon Cancer ◽  
Overall Survival Rates

Abstract Background It remains controversial whether patients with Stage II colon cancer would benefit from chemotherapy after radical surgery. This study aims to assess the real effectiveness of chemotherapy in patients with stage II colon cancer undergoing radical surgery and to construct survival prediction models to predict the survival benefits of chemotherapy. Methods Data for stage II colon cancer patients with radical surgery were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (1:1) was performed according to receive or not receive chemotherapy. Competitive risk regression models were used to assess colon cancer cause-specific death (CSD) and non-colon cancer cause-specific death (NCSD). Survival prediction nomograms were constructed to predict overall survival (OS) and colon cancer cause-specific survival (CSS). The predictive abilities of the constructed models were evaluated by the concordance indexes (C-indexes) and calibration curves. Results A total of 25,110 patients were identified, 21.7% received chemotherapy, and 78.3% were without chemotherapy. A total of 10,916 patients were extracted after propensity score matching. The estimated 3-year overall survival rates of chemotherapy were 0.7% higher than non- chemotherapy. The estimated 5-year and 10-year overall survival rates of non-chemotherapy were 1.3 and 2.1% higher than chemotherapy, respectively. Survival prediction models showed good discrimination (the C-indexes between 0.582 and 0.757) and excellent calibration. Conclusions Chemotherapy improves the short-term (43 months) survival benefit of stage II colon cancer patients who received radical surgery. Survival prediction models can be used to predict OS and CSS of patients receiving chemotherapy as well as OS and CSS of patients not receiving chemotherapy and to make individualized treatment recommendations for stage II colon cancer patients who received radical surgery.

scholarly journals Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score

EP Europace ◽  
2013 ◽  
Vol 16 (1) ◽  
pp. 40-46 ◽  
Author(s):  
K. Kraaier ◽  
M. F. Scholten ◽  
J. G. P. Tijssen ◽  
D. A. M. J. Theuns ◽  
L. J. L. M. Jordaens ◽  
...  
Keyword(s):  
Implantable Cardioverter Defibrillator ◽  
Risk Score ◽  
Early Mortality ◽  
Clinical Risk Score ◽  
Cardioverter Defibrillator ◽  
Clinical Risk ◽  
Development And Validation
Sign in / Sign up

Export Citation Format

Share Document